Metastatic Castrate-Resistant Prostate Cancer Treatment: Updates on Use of Darolutamide

Karim Fizazi, MD, PhD, provides a discussion on metastatic castrate-resistant prostate cancer and the use of darolutamide for management.

EP. 1: An Overview of Metastatic Castrate-Resistant Prostate Cancer

October 18th 2021

Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.

EP. 2: Systemic Therapy Options in Metastatic Castrate-Resistant Prostate Cancer

October 18th 2021

An oncologist explains treatment selection and the systemic therapy options available for patients with metastatic castrate-resistant prostate cancer.

EP. 3: Metastatic Castrate-Resistant Prostate Cancer: Androgen Receptor Inhibitors

October 18th 2021

Dr. Karim Fizazi describes the use of next generation androgen receptor inhibitors in treatment of metastatic castrate-resistant prostate cancer.

EP. 4: Darolutamide in Metastatic Castrate-Resistant Prostate Cancer

October 18th 2021

A key opinion leader discusses impact of ADTs on brain and cognitive function in men with prostate cancer.

EP. 5: The ODENZA Trial: Metastatic Castrate-Resistant Prostate Cancer

October 18th 2021

Karim Fizazi, MD, PhD, reviews darolutamide data in prostate cancer, including data from phase II clinical trial, ODENZA.

EP. 6: The Future of Metastatic Castrate-Resistant Prostate Cancer Management

October 18th 2021

An expert discusses the future of metastatic castrate-resistant prostate cancer management.